VAD & transplanted patient with non-cardiac critical illness by Dr Peta Alexander
Use of Ventricular Assist Devices (VAD) and heart transplantation (HT) for end stage cardiac failure have increased significantly in recent decades. These support strategies hold inherently different risks in the face on non-cardiac critical illness, and require multidisciplinary team management. According to INTERMACS, more than 2500 VADs/year are implanted the USA. Most implanted devices are continuous flow left-VADs (75%) which deliver systemic cardiac output directly related to pump speed and inversely related to pressure gradient across the pump. Improved survivorship has resulted in increasing outpatient management, however 12-month mortality is 12%, and <30% of patients are major-event free for 1-year. Critical illness may be device related, including cerebrovascular accidents, gastrointestinal bleeding, infection or multi-organ system dysfunction. Alternatively, presenting complaints may be unrelated to the device, with 23-27% of VAD patients undergoing non-cardiac surgery during support. Regardless of etiology, patient management is inherently linked to optimizing device function. Maintaining Left-VAD flow depends on adequate preload, supported right ventricular contractility and afterload reduction whilst managing systemic vascular resistance. Attention to associated coagulopathy, anti-inflammatory therapy and early institution of anti-microbial agents should be considered. HT is established therapy for end-stage heart failure, with more than 5000 HT reported to ISHLT in 2015. Complexity has increased due to comorbidities and recipient age. Etiologies of critical illness for HT patients include post-transplant complications such as acute rejection, graft failure and cardiac allograft vasculopathy. Acute rejection episodes affect >1/4 of patients within 1-year post-transplant. Systemic illnesses may also be associated with chronic immunosuppression, for example malignancy and unusual presentations of infectious disease; as well as medication toxicity where the post-transplant medication cocktail exacerbates underlying renal insufficiency and multi-organ dysfunction. Therapeutic interventions must also take into consideration potential drug-interactions. Recognizing and managing critical illness in the post-transplant population is exacerbated by vagal denervation blunting normal heart rate response, obscuring illness severity and limiting augmentation of cardiac output.
Recommended
More Related Content
Similar to VAD & transplanted patient with non-cardiac critical illness by Dr Peta Alexander
Similar to VAD & transplanted patient with non-cardiac critical illness by Dr Peta Alexander (18)
More from CICM 2019 Annual Scientific Meeting
More from CICM 2019 Annual Scientific Meeting (20)
Recently uploaded
Recently uploaded (20)
VAD & transplanted patient with non-cardiac critical illness by Dr Peta Alexander
- 1. VAD and Heart Transplanted Patients with Non-Cardiac Critical Illness Peta MA Alexander MBBS BSc(Hons) FRACP FCICM Staff Physician, Department of Cardiology Medical Lead, Cardiac ECMO Boston Children’s Hospital Harvard Medical School Boston, MA, USA peta.alexander@cardio.chboston.org
- 2. Site PI for Novartis serelaxin study Site PI for Tenax Therapeutics, Inc levosimendan study Member of Event Adjudication Committee for Entresto randomized control trial (Novartis) DISCLOSURES
- 3. Use of Ventricular Assist Devices and heart transplantation for end stage cardiac failure have increased significantly in recent decades.
- 4. These support strategies hold inherently different risks in the face of non-cardiac critical illness and require multidisciplinary team management VENTRICULAR ASSIST DEVICE
- 6. My HeartMate II has provided me with something that I thought I’d lost: time. Time to see my daughter grow up, time to spend with my husband, family and friends – time for another chance at truly living. LAURA Actual HeartMate II recipient and Cardiac Physical Therapist www.heartmate.com
- 12. Continuous Flow Left Ventricular Assist Devices: Dare to Compare. Goldstein DJ. The Journal of Thoracic and Cardiovascular Surgery (2015)
- 23. ISSUES Anticoagulation Associated Thrombosis Associated Infection Avoid Hypertension Always be on the lookout for Right Heart Failure
- 24. Single centre 445 patients Heartware HVAD and Heartmate II
- 37. Use of Ventricular Assist Devices and heart transplantation for end stage cardiac failure have increased significantly in recent decades. These support strategies hold inherently different risks in the face of non-cardiac critical illness and require multidisciplinary team management HEART TRANSPLANT
- 38. POST-TRANSPLANT ISSUES Rejection Rejection Rejection Rejection Rejection Rejection Rejection Graft Failure Vasculopathy Infections Malignancy
- 39. POST-TRANSPLANT ISSUES - PHARMACOTHERAPY Immunosuppression Neurotoxicity – TACROLIMUS (calcineurin inhibitors) Nephrotoxicity – TACROLIMUS (calcineurin inhibitors) Pulmonary Toxicity – SIROLIMUS, EVEROLIMUS (mTOR, proliferation signal inhibitors) Gastrointestinal Toxicity – mycophenolate mofetil
Editor's Notes
- Most illness associated thrombosis and the anticoagulation used to prevent this. Acquired VWF deficiency.